Key facts
- PIPr Therapeutics’s last known valuation is $10.0M (Nov 2025).
- It has raised $36.4M; the latest was Later Stage VC ($1.5M) in Nov 2025.
- Notable investors include Connecticut Innovations, AlleyCorp, Johnson & Johnson JJDC, Osage University Partners, Hatteras Venture Partners — 9 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 9 names
- ·Watchlist + deal alerts for PIPr Therapeutics
- ·The full record, as it builds
Funding rounds
No funding rounds for PIPr Therapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About PIPr Therapeutics
Developer of precision therapeutics designed to target and block the root causes of diverse, serious diseases triggered by intestinal inflammation. The company's therapeutics identify and characterize disease-driving bacteria from the intestinal microbiota to develop new and potentially curative treatments for unmet medical needs, enabling patients to have treatment options for several digestive disorders as well as other diseases, including obesity, autoimmune disease and a wide variety of skin, lung and central nervous system diseases.
- Sector
- Healthcare
- HQ
- New Haven, CT, United States
- Founded
- 2016
- Employees
- 19
- Website
- piprtx.com/
- Ownership
- Privately Held (backing)
PIPr Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in PIPr Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on PIPr Therapeutics in its N-PORT filings yet. We sweep new filings monthly.